109 related articles for article (PubMed ID: 15605307)
1. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.
Ghali P; Lindor KD
Semin Liver Dis; 2004 Nov; 24(4):389-97. PubMed ID: 15605307
[TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.
Chitturi S; George J
Semin Liver Dis; 2002; 22(2):169-83. PubMed ID: 12016548
[TBL] [Abstract][Full Text] [Related]
3. Obesity, hepatic metabolism and disease.
Edmison JM; Kalhan SC; McCullough AJ
Nestle Nutr Workshop Ser Pediatr Program; 2009; 63():163-72; discussion 172-6, 259-68. PubMed ID: 19346775
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
5. Oral hypoglycemic agents and heart.
Manoria P; Manoria P
Indian Heart J; 2007; 59(3):266-72. PubMed ID: 19124937
[No Abstract] [Full Text] [Related]
6. [Potential of combined hypoglycemic, antihypertensive, and hypolipidemic therapy in patients with diabetes mellitus and diabetic foot syndrome].
Onuchin SG; Elsukova OS; Onuchina EL
Klin Med (Mosk); 2008; 86(8):61-6. PubMed ID: 18819351
[TBL] [Abstract][Full Text] [Related]
7. Diabetes medications and body weight.
Mitri J; Hamdy O
Expert Opin Drug Saf; 2009 Sep; 8(5):573-84. PubMed ID: 19538102
[TBL] [Abstract][Full Text] [Related]
8. [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care].
Scholze J; Lilienthal W; Bramlage P
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():103-10. PubMed ID: 17955787
[TBL] [Abstract][Full Text] [Related]
9. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
Marković BB; Kranjcević K; Reiner Z; Blazeković SM; Spehar SS
Croat Med J; 2005 Dec; 46(6):984-9. PubMed ID: 16342354
[TBL] [Abstract][Full Text] [Related]
10. Primary care issues in patients with mental illness.
Kiraly B; Gunning K; Leiser J
Am Fam Physician; 2008 Aug; 78(3):355-62. PubMed ID: 18711951
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.
Uwaifo GI; Ratner RE
Am J Cardiol; 2007 Feb; 99(4A):51B-67B. PubMed ID: 17307058
[TBL] [Abstract][Full Text] [Related]
12. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
14. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
[TBL] [Abstract][Full Text] [Related]
15. The treatment of NAFLD.
Trappoliere M; Tuccillo C; Federico A; Di Leva A; Niosi M; D'Alessio C; Capasso R; Coppola F; Dauria M; Loguercio C
Eur Rev Med Pharmacol Sci; 2005; 9(5):299-304. PubMed ID: 16231594
[TBL] [Abstract][Full Text] [Related]
16. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
17. Obesity and related diseases: an epidemiologic study in eastern Sicily.
Bertino G; Ardiri AM; Alì FT; Boemi PM; Cilio D; Di Prima P; Fisichella A; Ierna D; Neri S; Pulvirenti D; Urso G; Mauceri B; Valenti M; Bruno CM
Minerva Gastroenterol Dietol; 2006 Dec; 52(4):379-85. PubMed ID: 17108868
[TBL] [Abstract][Full Text] [Related]
18. Effects of weight loss on nonalcoholic fatty liver disease.
Rafiq N; Younossi ZM
Semin Liver Dis; 2008 Nov; 28(4):427-33. PubMed ID: 18956298
[TBL] [Abstract][Full Text] [Related]
19. [Lifestyle, socioeconomic status and morbidity in postmenopausal women with grade II and III obesity].
Navarro Rodríguez MC; Saavedra Santana P; de Pablos Velasco P; Sablón González N; de Miguel Ruiz E; Castro Medina R; Sosa Henríquez M
Endocrinol Nutr; 2009 May; 56(5):227-32. PubMed ID: 19627743
[TBL] [Abstract][Full Text] [Related]
20. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Walker AM; Koro CE; Landon J
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):760-8. PubMed ID: 18383443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
